Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

afr.com - Michael Smith - Mayne Pharma lands $604m bid from Hungarian drugs group
Mayne Pharma lands $604m bid from Hungarian drugs group
Australian Financial Review –

Hungarian drug maker Gedeon Richter has made a $604 million takeover bid for Mayne Pharma just a week after Mayne announced plans to sell its Adelaide manufacturing plant. Gedeon Richter's offer of $6.40 a share in cash is almost double Mayne's…

afr.com - Mayne Pharma rockets 79pc on takeover bid; Chalmers aims to cut red tape on tax; Gilbert + Tobin private equity partner resigns
Mayne Pharma rockets 79pc on takeover bid; Chalmers aims to cut red tape on tax; Gilbert + Tobin private equity partner resigns
Australian Financial Review –

Want to get this in your inbox at lunchtime every weekday? Financial Review subscribers can sign up for The Brief newsletter here. Plus start your day with our Before the Bell newsletter and read a full wrap of the day's news in Market Wrap. In…

thehindubusinessline.com - BL Mumbai Bureau - DRI search at Cipla involving imported pharma product
DRI search at Cipla involving imported pharma product
The HinduBusinessLine –

Updated - November 17, 2026 at 12:56 PM. | Mumbai Drugmaker Cipla said that the Directorate of Revenue Intelligence (Mumbai zonal unit) had conducted a search at its office in Vikhroli, Mumbai, and at its depot in Bhiwandi, Thane. The search on…

thehindubusinessline.com -  PTI - AstraZeneca Pharma India inks agreement with Strand Life Sciences to explore healthcare collaboration
AstraZeneca Pharma India inks agreement with Strand Life Sciences to explore healthcare collaboration
The HinduBusinessLine –

Updated - November 17, 2026 at 04:13 PM. | New Delhi, Nov 17 AstraZeneca Pharma India Ltd on Tuesday said it has signed a letter of intent (LoI) with Strand Life Sciences Pvt Ltd to explore opportunities to collaborate in healthcare in India.

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Stock Falls 8.1% Following Analyst Downgrade
Avalyn Pharma (NASDAQ:AVLN) Stock Falls 8.1% Following Analyst Downgrade
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) traded down 8.1% on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma traded…

marketbeat.com - Teachers Retirement System of The State of Kentucky Buys 415,100 Shares of Royalty Pharma PLC $RPRX
Teachers Retirement System of The State of Kentucky Buys 415,100 Shares of Royalty Pharma PLC $RPRX
MarketBeat –

Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Stock Falls 10.1% - What's Next?
Spyglass Pharma (NASDAQ:SGP) Stock Falls 10.1% - What's Next?
MarketBeat –

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) traded down 10.1% during trading on Monday. The stock traded as low as $30.00 and last traded at $29.5510. 32,138 shares traded hands during trading, a decline of 70% from the average…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
MarketBeat –

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares trading…

seekingalpha.com - Fred Piard - PJP: Healthcare Sector Dashboard For November
PJP: Healthcare Sector Dashboard For November
Seeking Alpha –

The healthcare equipment industry is undervalued based on historical averages, while pharma/biotechnology is significantly overvalued. Invesco Pharmaceuticals ETF (PJP) offers multi-factor pharmaceutical exposure suited to long-term and tactical…

the-decoder.com - Manuel Uth - Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
The Decoder –

Because Moonshot AI sees diminishing returns in coding, the Beijing startup is redirecting its Kimi language models toward biology, chemistry, and pharma research. International director Giacomo Ficari said at the Web Summit in Lisbon that science…

techcrunch.com - Ram Iyer - Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
TechCrunch –

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The funding was co-led by Greenoaks and…

crunchbase.com - Mary Ann Azevedo - PwC's IPO Lead On A Selective Market, AI Valuations And The Outlook For 2027
PwC's IPO Lead On A Selective Market, AI Valuations And The Outlook For 2027
Crunchbase –

The U.S. IPO market has rebounded, but the recovery remains uneven. Companies seeking to go public face investors focused on durable revenue, profitability and valuation, while uncertainty has prompted some issuers to postpone their offerings. Mike…

statnews.com - Andrew Joseph - FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
STAT –

The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as…

cnbc.com - Natasha Abellard - Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
CNBC –

Johnson & Johnson is a prime example of the kind of stock doing well in the broader market as investors shy away from the volatile artificial intelligence trade. '[J & J] is a metaphor for what's working,' Jim Cramer said Monday on CNBC, as shares…

statnews.com - Margaret Manto - In a win for MAHA, FDA creates new regulatory category for the supplement NAC
In a win for MAHA, FDA creates new regulatory category for the supplement NAC
STAT –

WASHINGTON – The Food and Drug Administration is proposing a new classification for a product that's existed in a legal grey area for years, a win for proponents of dietary supplements, including members of the MAHA movement. The proposed…

Receive a Daily briefing on Pharma Industry News

Get Started